NCT00809848 - Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Ocular HypertensionGlaucoma

Interventions

DRUG

AGN-210669 ophthalmic solution, 0.075%

AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.

DRUG

AGN-210669 ophthalmic solution, 0.05%

AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.

DRUG

AGN-210669 ophthalmic solution, 0.025%

AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.

DRUG

bimatoprost ophthalmic solution 0.03%

Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.

DRUG

AGN-210669 vehicle ophthalmic solution

AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.

Trial Locations (1)

Artesia